WAGENHEIM PHILIP 4

What Happened
Philip Wagenheim, a director of Immunome Inc. (IMNM), received a grant of 9,897 derivative securities on June 10, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant). This transaction is an award/grant (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Amount: 9,897 derivative shares/options granted at $0.00 per share.
• Vesting: Vests in four equal quarterly installments starting June 10, 2026 through the one-year anniversary (see footnote). Continuous service required for each vesting date.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: Vesting occurs in four equal quarterly installments commencing June 10, 2026, subject to continuous service.
• Filing timeliness: Reported within the standard Form 4 window (appears timely).

Context
This was a company grant to a director (an award of derivative securities) rather than a purchase or sale. Such awards typically compensate service and may vest over time; they do not by themselves signal a director buying or selling stock. The grant price listed as $0.00 means no cash was paid at grant; the economic value depends on the award type and the company’s valuation and vesting.